Share ownership Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:25:00 17/04/2026 pm IST			5-day change	1st Jan Change
82.02 ^EUR	+1.45%		+2.28%	-0.85%

18/04	Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike in Head-To-Head Study	CI
18/04	Sanofi's Nuvaxovid Covid-19 vaccine showed better tolerability than Mnexspike in head-to-head study	RE

Share class: Sanofi

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,26,31,22,721	1,10,28,39,922 ( 87.31 %)	1,53,30,000 ( 1.214 %)	87.31 %

Major shareholders: Sanofi

Name	Equities	%	Valuation
L'ORÉAL 7.315 %	8,86,70,657	7.315 %	8 451 M €
SANOFI 0.9869 %	1,19,62,777	0.9869 %	1 140 M €
OFI Invest Asset Management SA 0.2883 %	34,94,559	0.2883 %	333 M €
State Street Global Advisors Ltd. 0.1419 %	17,20,600	0.1419 %	164 M €
Sjunde AP-fonden 0.135 %	16,36,863	0.135 %	156 M €
Capfi Delen Asset Management NV 0.0898 %	10,88,070	0.0898 %	104 M €
Goldman Sachs Asset Management BV 0.0882 %	10,68,764	0.0882 %	102 M €
Sparinvest SA (Denmark) 0.0764 %	9,25,940	0.0764 %	88 M €
Pacer Advisors, Inc. 0.0672 %	8,14,404	0.0672 %	78 M €
Nordea Investment Management AB (Norway) 0.0668 %	8,09,989	0.0668 %	77 M €
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Dodge & Cox 2.33 %	5,64,92,599	2.33 %	2 722 M €
Fisher Asset Management LLC 0.5008 %	1,21,40,615	0.5008 %	585 M €
Eaton Vance Management 0.3754 %	91,02,196	0.3754 %	439 M €
Merrill Lynch International 0.3524 %	85,44,008	0.3524 %	412 M €
Barrow, Hanley, Mewhinney & Strauss LLC 0.2874 %	69,68,413	0.2874 %	336 M €
Invesco Advisers, Inc. 0.2521 %	61,10,874	0.2521 %	294 M €
Fiduciary Trust Company International 0.2104 %	51,00,097	0.2104 %	246 M €
Mondrian Investment Partners Ltd. 0.1854 %	44,95,348	0.1854 %	217 M €
Wells Fargo Bank NA 0.1832 %	44,42,532	0.1832 %	214 M €
Federated Investment Counseling 0.1502 %	36,42,307	0.1502 %	175 M €
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	19.35%
L'Oréal SA	7.31%
Other	1.54%
Sanofi	0.99%
Regal Partners Ltd.	0.16%
SEI Investments Co.	0.05%
Zions Bancorporation NA	0.01%
Northwest Bancshares, Inc. (Pennsylvania)	0.01%
Unknown	70.58%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	15.69%
France	9%
United Kingdom	2.14%
Canada	0.5%
Ireland	0.21%
Spain	0.21%
Germany	0.19%
Sweden	0.17%
Belgium	0.17%
Norway	0.17%
Australia	0.17%
Netherlands	0.12%
Denmark	0.11%
Switzerland	0.11%
Italy	0.1%
Finland	0.08%
Luxembourg	0.07%
Austria	0.04%
New Zealand	0.03%
South Africa	0.02%
Hong Kong	0.02%
Japan	0.02%
Israel	0.02%
Cyprus	0.01%
China	0.01%
Liechtenstein	0.01%
Puerto Rico	0.01%
Mexico	0.01%
Individuals	-.--%

Based on 1000 largest holdings

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).

Employees

74,846

Sector

Pharmaceuticals

Calendar

23/04 - Earnings release - Q1 2026

More about the company